Drugs Made In America Acquisition II Corp. (DMII) stock
DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.23−0.01 (-0.15%)
Close on Nov 18, 2026Market cap $140.15MP/E –Yield –
Drugs Made In America Acquisition II operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Drugs Made In America Acquisition II's operating income for the twelve months ending Sep 30, 2026 was -$556.74K. For fiscal 2025 it was -$488.39K.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$488.39K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$77.01K | – |
| Q2 FY2026 | Jun 30, 2026 | -$112.23K | – |
| Q1 FY2026 | Mar 31, 2026 | -$132.03K | – |
| Q4 FY2025 | Dec 31, 2025 | -$235.47K | – |
| Q3 FY2025 | Sep 30, 2025 | -$155.51K | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.07K | – |
| Q1 FY2025 | Mar 31, 2025 | -$59.33K | – |
See a number that looks wrong?